El interés en corto de Tenon Medical da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Tenon Medical. Los datos de interés en corto se actualizan cada dos semanas.

Tenon Medical (NASDAQ:TNON) Bolsa, Informe de interés en corto

Tenon Medical

Tenon Medical Inc is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.

Tenon Medical Inc

HNI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HNI#NYSE">HNI</a>) announced today its Board of Directors declared a quarterly dividend of 34 cents per share on its common stock.
The dividend will be payable on June 11, 2025, to shareholders of record at the close of business on May 23, 2025.

News

Dividends

HNI Corporation Increases Quarterly Dividend From $0.33 To $0.34 Per Share

Barclays analyst Theresa Chen maintains Valero Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLO#NYSE">VLO</a>) with a Overweight and raises the price target from $140 to $141.

Price Target

Analyst Ratings

Barclays Maintains Overweight on Valero Energy, Raises Price Target to $141

HighPeak Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HPK#NASDAQ">HPK</a>) reported quarterly earnings of $0.31 per share which beat the analyst consensus estimate of $0.29 by 6.9 percent. This is a 16.22 percent decrease over earnings of $0.37 per share from the same period last year. The company reported quarterly sales of $257.45 million which beat the analyst consensus estimate of $249.18 million by 3.32 percent. This is a 10.54 percent decrease over sales of $287.76 million the same period last year.

Earnings

Earnings Beats

CORRECTION: HighPeak Energy Q1 Adj. EPS $0.31 Beats $0.29 Estimate, Sales $257.45M Beat $249.18M Estimate

Barclays analyst Ramsey El-Assal maintains Upstart Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) with a Equal-Weight and raises the price target from $42 to $47.

UPST

Barclays Maintains Equal-Weight on Upstart Hldgs, Raises Price Target to $47

Hertz Global Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTZ#NASDAQ">HTZ</a>) reported quarterly losses of $(1.12) per share which missed the analyst consensus estimate of $(0.97) by 15.46 percent. This is a 12.5 percent increase over losses of $(1.28) per share from the same period last year. The company reported quarterly sales of $1.81 billion which missed the analyst consensus estimate of $2.00 billion by 9.46 percent. This is a 12.84 percent decrease over sales of $2.08 billion the same period last year.

Earnings Misses

Hertz Global Holdings Q1 Adj. EPS $(1.12) Misses $(0.97) Estimate, Sales $1.81B Miss $2.00B Estimate

Barclays analyst Tim Long maintains Ubiquiti (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UI#NYSE">UI</a>) with a Underweight and raises the price target from $222 to $247.

Barclays Maintains Underweight on Ubiquiti, Raises Price Target to $247

Camber Energy (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CEIN#OTC">CEIN</a>) reported $5.40 million in sales this quarter. This is a 29.44 percent decrease over sales of $7.65 million the same period last year.

CEIN

Camber Energy Q4 Sales $5.40M Down From $7.65M YoY

Kayne Anderson BDC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBDC#NYSE">KBDC</a>) reported quarterly earnings of $0.40 per share which missed the analyst consensus estimate of $0.42 by 4.76 percent. The company reported quarterly sales of $55.24 million which missed the analyst consensus estimate of $58.43 million by 5.46 percent.

KBDC

CORRECTION: Kayne Anderson BDC Q1 EPS $0.40 Misses $0.42 Estimate, Sales $55.24M Miss $58.43M Estimate

Barclays analyst Adrienne Yih maintains Gap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) with a Overweight and lowers the price target from $33 to $26.

Barclays Maintains Overweight on Gap, Lowers Price Target to $26

Dynatronics (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DYNT#OTC">DYNT</a>) reported quarterly losses of $(0.13) per share. This is a 23.53 percent increase over losses of $(0.17) per share from the same period last year. The company reported $6.15 million in sales this quarter. This is a 19.67 percent decrease over sales of $7.66 million the same period last year.

DYNT

Dynatronics Q3 GAAP EPS $(0.13) Up From $(0.17) YoY, Sales $6.15M Down From $7.66M YoY

Barclays analyst Adrienne Yih maintains Tapestry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>) with a Overweight and raises the price target from $83 to $98.

Barclays Maintains Overweight on Tapestry, Raises Price Target to $98

Barclays analyst John Coffey maintains StoneCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>) with a Equal-Weight and raises the price target from $13 to $15.

STNE

Barclays Maintains Equal-Weight on StoneCo, Raises Price Target to $15

LSEA

Apollo Global Management Portfolio Company, New Home Co. Has Entered Into A Definitive Agreement Under Which It Will Acquire Landsea Homes For $11.30 Per Share In An All-Cash Transaction

OptimumBank Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPHC#NASDAQ">OPHC</a>) reported quarterly earnings of $0.32 per share. This is a 3.23 percent increase over earnings of $0.31 per share from the same period last year. The company reported $10.66 million in sales this quarter. This is a 18.54 percent increase over sales of $8.99 million the same period last year.

OPHC

OptimumBank Hldgs Q1 EPS $0.32 Up From $0.31 YoY, Sales $10.66M Up From $8.99M YoY

New Found Gold (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NFGC#AMEX">NFGC</a>) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.06) by 50 percent. This is a 40 percent increase over losses of $(0.05) per share from the same period last year.

NFGC

New Found Gold Q1 GAAP EPS $(0.03) Beats $(0.06) Estimate

Barclays analyst Ramsey El-Assal maintains Remitly Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RELY#NASDAQ">RELY</a>) with a Overweight and raises the price target from $24 to $27.

RELY

Barclays Maintains Overweight on Remitly Global, Raises Price Target to $27

Barclays analyst Theresa Chen maintains Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) with a Equal-Weight and raises the price target from $106 to $115.

Barclays Maintains Equal-Weight on Phillips 66, Raises Price Target to $115

ORIX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IX#NYSE">IX</a>) reported quarterly earnings of $0.46 per share. This is a 37.84 percent decrease over earnings of $0.74 per share from the same period last year. The company reported $4.72 billion in sales this quarter. This is a 9.75 percent decrease over sales of $5.23 billion the same period last year.

ORIX Q4 EPS $0.46 Down From $0.74 YoY, Sales $4.72B Down From $5.23B YoY

Bone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.48) by 33.33 percent. This is a 75.57 percent increase over losses of $(1.31) per share from the same period last year.

BBLG

Bone Biologics Q1 EPS $(0.32) Beats $(0.48) Estimate

Infinity Natural (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INR#NYSE">INR</a>) reported $85.17 million in sales this quarter. This is a 69.57 percent increase over sales of $50.23 million the same period last year.

Morgan Stanley Market Vectors Rupee/USD ETN

Infinity Natural Q1 Sales $85.17M Up From $50.23M YoY

Press Releases

Tenon Medical(R) to Host Meetings During the 2025 J.P. Morgan Healthcare Conference in San Francisco

Tenon Medical, Inc. Announces Timing of Fourth Quarter and Full Year 2024 Financial Results

Tenon Medical(R) Receives Approval for Notice of Allowance from the European Patent Office

Tenon Medical, Inc. Announces a Warrant Inducement Transaction for $3.0 Million in Gross Proceeds

Tenon Medical Reports Fourth Quarter and Full Year 2024 Financial Results

Tenon Medical(R) Announces FDA Clearance of Catamaran(R) SI Joint Fusion System for New Indication to Augment Spinal Fusion

Tenon Medical, Inc. Announces a Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Breakthroughs and Discoveries: TNON, PNPN.V, POAI, DYAI, PRSO, Drive Innovation Across Sectors

Tenon Medical, Inc. Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Comments

Tenon Medical

Interés en corto

Tenon Medical (NASDAQ:TNON) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL